Form 4 for PMN ProMIS Neurosciences Inc.

Accepted 2026-02-05 00:00:00 ET · period of report 2026-02-03 · accession 0001104659-26-011138 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-02-05	2026-02-03	PMN	Warma Neil K	CEO, Dir	A - Grant	$12.13	+6,183	6,183	New	+$75.0K
D	2026-02-05	2026-02-03	PMN	Warma Neil K	CEO, Dir	A - Grant	—	+6,183	6,183	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2026-02-03	A	A	6,183	$12.13	6,183	D	—	—	(F1) On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
2	Derivative	Warrants to purchase Common Shares	2026-02-03	A	A	6,183	—	6,183	D	$14.40 · 2026-02-03 to 2031-02-03	6,183 Common Shares	(F1) On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. (F2) The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.